Dr Clare Hoskins

Title: Senior Lecturer in Pharmaceutics
Phone: 01782 734799
Email: c.hoskins@keele.ac.uk
Location: Hornbeam Building, Room 0.48
Role: ISTM Research theme: Therapeutics
MPharm teaching
Contacting me: Phone/Email
Clare Hoskins

I joined the School of Pharmacy as a lecturer in pharmaceutics in 2011. Here I teach on the MPharm course and continue my research interest in nanomedicines. I completed my PhD in pharmaceutics at the Robert Gordon University in Aberdeen, Scotland in 2009.  I then worked as a postdoctoral researcher at the Institute of Medical Science and Technology at the University of Dundee. Here I investigated the potential use of magnetic nanoparticles for nerve regeneration in the peripheral nervous system.  Now my work focuses on the investigation into hybrid metallic nanoparticles as multifunctional vehicles for imaging and targeted drug delivery for pancreatic cancer. I am a member of both the Royal Society of Chemistry and the UK and Ireland Controlled Release Society.

ISTM Research theme: Therapeutics

Pancreatic cancer is the fourth main cancer in the western world. Pancreatic resection is currently the only treatment known for this cancer with only 5-34% of patients surviving 5 years after treatment. Currently the only chemotherapy available clinically is gemcitabine which only proves effective in 23.8% of patients. Therefore there is a huge clinical need for increasing the efficiency of this treatment as well as exploring alternative therapies.

Magnetic iron oxide nanoparticles (MNPs) have become widely studied for biomedical applications in recent years including magnetic resonance imaging (MRI), drug and gene therapy. In order for these MNP's to be safe they are coated with materials such as silica and polymers. However, increasing safety concerns over the use of polymer coated MNPs has arisen. For example degradation of the flexible polymer coats results in exposure of iron oxide leading to increased toxicity. This unwanted side effect has led to the recent withdrawal of Feridex®, the clinically used MRI contrast agent. Gold is renowned for its chemical stability and biocompatibility and surface plasmon resonance. Surface coating of the MNPs results in a rigid coat shielding the external environment from the iron oxide. This results in safer particles with increased applications. Surface functionalization of gold nanoparticles can be carried out through thiol (–SH) group conjugation forming relatively stable bonds. When nanoparticles are irradiated, the SPR absorption of Au nanoparticles is followed by rapid conversion of light into heat. In biomedicine this unique property can be exploited for applications such as photo thermal ablation and thermo responsive drug delivery. Clinically, the optimal wavelengths for laser irradiation of AuNPs is within the ‘biological near infrared region (NIR)’. Laser beams inside the NIR window are capable of deep tissue penetration due to the high tramisivity of water and haemoglobin within these wavelengths. This can be exploited for non-invasive or minimally invasive therapy.

I am interested in the fabrication of hybrid iron oxide-gold core-shell nanostructures with strong magnetism, biocompatibility and surface plasmon resonance. Conjugation of drug molecules onto particle surface results in the capability for image guided thermoresponsive drug delivery. Preliminary data for these hybrid nanoparticles has highlighted the great potential for pancreatic cancer therapy. Use of these hybrids as delivery vehicles reduces invasive procedures and increases therapeutic efficacy whilst minimising patient side effects.

Nanopharmaceutics: Please click here for a link to our group website.

Selected Publications

  • Chandarana M, Curtis A, Hoskins C. 2018. The use of nanotechnology in cardiovascular disease. APPLIED NANOSCIENCE, vol. 8(7), 1607-1619. link> doi> full text>
  • Alsuraifi A, Lin PKT, Curtis A, Lamprou DA, Hoskins C. 2018. A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines. Pharmaceuticals (Basel), vol. 11(4). link> doi> full text>
  • Alsuraifi A, Curtis A, Lamprou DA, Hoskins C. 2018. Stimuli Responsive Polymeric Systems for Cancer Therapy. Pharmaceutics, vol. 10(3). link> doi> full text>
  • Al-Shakarchi W, Alsuraifi A, Curtis A, Hoskins C. 2018. Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy. Pharmaceutics, vol. 10(2). link> doi> full text>
  • Al-Shakarchi W, Alsuraifi A, Abed M, Abdullah M, Richardson A, Curtis A, Hoskins C. 2018. Combined Effect of Anticancer Agents and Cytochrome C Decorated Hybrid Nanoparticles for Liver Cancer Therapy. Pharmaceutics, vol. 10(2). link> doi> full text>

Full Publications List show

Journal Articles

  • Chandarana M, Curtis A, Hoskins C. 2018. The use of nanotechnology in cardiovascular disease. APPLIED NANOSCIENCE, vol. 8(7), 1607-1619. link> doi> full text>
  • Alsuraifi A, Lin PKT, Curtis A, Lamprou DA, Hoskins C. 2018. A Novel PAA Derivative with Enhanced Drug Efficacy in Pancreatic Cancer Cell Lines. Pharmaceuticals (Basel), vol. 11(4). link> doi> full text>
  • Alsuraifi A, Curtis A, Lamprou DA, Hoskins C. 2018. Stimuli Responsive Polymeric Systems for Cancer Therapy. Pharmaceutics, vol. 10(3). link> doi> full text>
  • Al-Shakarchi W, Alsuraifi A, Curtis A, Hoskins C. 2018. Dual Acting Polymeric Nano-Aggregates for Liver Cancer Therapy. Pharmaceutics, vol. 10(2). link> doi> full text>
  • Al-Shakarchi W, Alsuraifi A, Abed M, Abdullah M, Richardson A, Curtis A, Hoskins C. 2018. Combined Effect of Anticancer Agents and Cytochrome C Decorated Hybrid Nanoparticles for Liver Cancer Therapy. Pharmaceutics, vol. 10(2). link> doi> full text>
  • Moss DM, Curley P, Kinvig H, Hoskins C, Owen A. 2018. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Expert Rev Gastroenterol Hepatol, vol. 12(3), 223-236. link> doi> full text>
  • Kumar M, Curtis A, Hoskins C. 2018. Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance. Pharmaceutics, vol. 10(1). link> doi> full text>
  • Zafar A, Pilkington LI, Haverkate NA, van Rensburg M, Leung E, Kumara S, Denny WA, Barker D, Alsuraifi A, Hoskins C, Reynisson J. 2018. Investigation into Improving the Aqueous Solubility of the Thieno[2,3-b]pyridine Anti-Proliferative Agents. Molecules, vol. 23(1). link> doi> full text>
  • Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. 2017. Nanotechnologies in Pancreatic Cancer Therapy. Pharmaceutics, vol. 9(4). link> doi> full text>
  • Oluwasanmi A, Al-Shakarchi W, Manzur A, Aldebasi MH, Elsini RS, Albusair MK, Haxton KJ, Curtis ADM, Hoskins C. 2017. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy. J Control Release, vol. 266, 355-364. link> doi> full text>
  • Malekigorji M, Alfahad M, Kong Thoo Lin P, Jones S, Curtis A, Hoskins C. 2017. Thermally triggered theranostics for pancreatic cancer therapy. Nanoscale, vol. 9(34), 12735-12745. link> doi> full text>
  • de Wolf E, Abdullah MI, Jones SM, Menezes K, Moss DM, Drijfhout FP, Hart SR, Hoskins C, Stronach EA, Richardson A. 2017. Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer. Sci Rep, vol. 7(1), 5410. link> doi> full text>
  • Mathur S and Hoskins C. 2017. Drug development: Lessons from nature. Biomed Rep, vol. 6(6), 612-614. link> doi> full text>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2017. Further correction: Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy (vol 6, 60126, 2016). RSC ADVANCES, vol. 7(28), 17367. link> doi> full text>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2017. Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC ADVANCES, vol. 7(21), 12598. link> doi> link> full text>
  • Oluwasanmi A, Malekigorji M, Jones S, Curtis A, Hoskins C. 2016. Potential of hybrid iron oxide-gold nanoparticles as thermal triggers for pancreatic cancer therapy. RSC ADVANCES, vol. 6(97), 95044-95054. link> doi> full text>
  • Robinson E, Jones S, Menezes K, Abdullah M, Stronach E, Hoskins C, Richardson A. 2016. Pitavastatin is a potential treatment for drug-resistant ovarian cancer. EUROPEAN JOURNAL OF CANCER, vol. 61, S192. link> doi>
  • Khare V, Al Sakarchi W, Gupta PN, Curtis ADM, Hoskins C. 2016. Synthesis and characterization of TPGS-gemcitabine prodrug micelles for pancreatic cancer therapy. RSC ADVANCES, vol. 6(65), 60126-60137. link> doi> full text>
  • Hoskins C, Papachristou A, Ho TMH, Hine J, Curtis ADM. 2016. Investigation into drug solubilisation potential of sulfonated calix[4]resorcinarenes. Journal of Nanomedicine and Nanotechnology, vol. 7, Article 2. doi> full text>
  • Curtis ADM, Malekigorji M, Holman J, Skidmore M, Hoskins C. 2015. Heat Dissipation of Hybrid Iron Oxide-Gold Nanoparticles in an Agar Phantom. Journal of Nanomedicine and Nanotechnology. doi> full text>
  • Hoskins C and Curtis ADM. 2015. Simple Calixarenes and Resorcinarenes as Drug Solubilizing Agents. Journal of Nanomedicine Research, vol. 2(3), Article 28. doi>
  • Malekigorji M, Hoskins C, Curtis ADM, Varbiro G. 2014. Enhancement of the Cytotoxic Effect of Anticancer Agent by Cytochrome c Functionalised Hybrid Nanoparticles in Hepatocellular Cancer Cells. Journal of Nanomedicine Research, vol. 2(1), Article 10. doi>
  • Malekigorji M, Curtis ADM, Hoskins C. 2014. The Use of Iron Oxide Nanoparticles for Pancreatic Cancer Therapy. Journal of Nanomedicine Research, vol. 1(1), 1-12. doi>
  • Barnett C, Lees M, Curtis ADM, Kong Thoo Lin P, Cheng WP, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery. Pharmaceutical Nanotechnology, vol. 1(3), 224-238. doi>
  • Calatayud MP, Riggio C, Sanz B, Torres TE, Ibarra MR, Hoskins C, Cuschieri A, Wang L, Goya GF. 2013. Magnetic loading of human neuroblastoma cells for magnetically assisted neural guidance. Journal of Materials Chemistry B, vol. 1, Article 3607.
  • Barnett C, Gueorguieva M, Lees M, McGarvey D, Hoskins C. 2013. Physical stability, biocompatibility and potential use of hybrid iron oxide-gold nanoparticles as drug carriers. Journal of Nanoparticle Research, Article 1706. doi>
  • Roach P, McGarvey DJ, Lees MR, Hoskins C. 2013. Remotely triggered scaffolds for controlled degradation and release of pharmaceuticals. International Journal of Molecular Sciences, 8585-8602. doi> full text>
  • Riggio C, Raffa V, Calatayud MP, Sanz B, Torres TE, Ibarra, Goya GF, Hoskins C, Wang L, Cuschieri A. 2012. Poly-l-lysine coated magnetic nanoparticles as intracellular actuators for neural guidance. International Journal of Nanomedicine, vol. 2012(7), 3155-3166. doi> link>
  • Hoskins C, Cuschieri A, Wang L. 2012. The cytotoxicity of polycationic iron oxide nanoparticles: Common endpoint assays and alternative approaches for improved understanding of cellular response mechanism. Journal of Nanobiotechnology, vol. 10(15), Article 15. doi> link> full text>
  • Hoskins C, Kong Thoo Lin P, Cheng WP. 2012. A review on comb-shaped amphiphilic polymers for hydrophobic drug solubilization. Therapeutic Delivery, 59-79.
  • Chen S, Hoskins C, Wang L, MacDonald MP, Andre P. 2012. A water-soluble temperature nanoprobe based on a multimodal magnetic-luminescent nanocolloid. Chemical Communications, 2501-2503.
  • Hoskins C, Wang L, Cheng WP, Cuschieri A. 2012. Dilemmas in the reliable estimation of the in vitro cell viability in magnetic nanoparticle engineering: which tests and what protocols?. Nanoscale Research Letters, 77.
  • Barnett C, Gueorguieva M, Lees M, Darton R, McGarvey D, Hoskins C. 2012. Effect of hybrid composition on physicochemical properties and morphology of iron oxide-gold nanoparticles. Journal of Nanoparticle Research. doi>
  • Hoskins C, Min Y, Volvick A, McDougall C, Gueorguieva M, Cuschieri A, Wang L. 2012. Hybrid gold-iron oxide nanoparticles as a multifunctional platform for biomedical application. Journal of Nanobiotechnology, Article 27.
  • Hoskins C and Cheng WP. 2012. Implementing Nanotechnology and Novel Drug Delivery Systems to Improve Dissolution and Solubilization. Amercican Pharmaceutical Review.
  • Hoskins C, Kong Thoo Lin P, Tetley L, Cheng WP. 2012. The use of nano polymeric self-assemblies based on novel amphiphilic polymers for oral hydrophobic drug delivery. Pharmaceutical Research, 59-79.
  • Gu J, Cheng WP, Hoskins C, Kong Thoo Lin P, Zhao L, Zhu L, Qu X, Yang Z. 2011. Nano self-assemblies based on cholate grafted poly-L-lysine enhanced the solubility of sterol-like drugs. Journal of Microencapsulation, vol. 8(28), 752-762.
  • Hoskins C, Kong Thoo Lin P, Tetley L, Cheng WP. 2011. Novel fluorescent amphiphilic poly(allylamine) and their supramolecular self-assemblies in aqueous media. Polymers for Advanced Technologies. doi>
  • Hoskins C, Ouaissi M, Lima SC, Cheng WP, Loureirio I, Mas E, Lombardo D, Cordeiro-da-Silva A, Ouaissi A, Kong Thoo Lin P. 2010. In vitro and in vivo anticancer activity of a novel nano-sized formulation based on self-assembling polymers against pancreatic cancer. Pharmaceutical Research, 2694-2703. doi>
  • berry S, hoskins C, telling N, Price HP. FORTHCOMING: Magnetic nanoparticles as a novel treatment of cutaneous leishmaniasis. ACS Nano.
  • Calatayud MP, Riggio C, Raffa V, Sanz B, Torres TE, Ibarra MR, Hoskins C, Cuschieri A, Wang L, Goya GF. Magnetic Loading of Human Neuroblastoma Cells for magnetically assisted neural guidance.

Chapters

  • Curtis ADM and Hoskins C. 2015. Potential Use of Hybrid Iron Oxide-Gold as Drug Carriers. In Nano Based Drug Delivery. IAPC-OBC. doi>
  • Malekigorji M and Hoskins C. 2015. Smart Materials with Future Application in Drug Delivery. In Intelligent Drug Delivery Systems. Future Science.
  • Hoskins C and Cheng WP. 2013. Hydrophobic Drug Solubilisation. In Fundamentals in Pharmaceutical Nanoscience. Springer.

Other

  • Robinson E, Abdullah M, Jones S, Menezes K, Euan S, Hoskins C, Richardson A. 2016. Preclinical evaluation of pitavastatin as a treatment for chemotherapy-resistant ovarian cancer. EUROPEAN JOURNAL OF CANCER (vol. 69, p. S150). link> doi>
  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. 2016. Thermally triggered theranostics for pancreatic cancer. European journal of cancer (vol. 61, p. S129). Elsevier. doi> full text>
  • Malekigorji M, Lin PKT, Lees M, Gueorguieva M, Curtis A, Hoskins C. 2016. Thermally triggered theranostics for pancreatic cancer. EUROPEAN JOURNAL OF CANCER (vol. 61, p. S129). link>
  • Hoskins C. 2015. Sexism in peer review.
  • Hoskins C. 2015. Novel Nano-systems / Theranostic advances.
  • Hoskins C. 2010. A brief history of amphiphilic polymers.
  • Cheng WP, Kong Thoo Lin P, Hoskins C. Amphiphilic polymers witih aromatic pendants for drug delivery.
  • Andre P, Chen S, Hoskins C, Wang L, MacDonald MP. External Monitoring of in-situ Temperatures with Multimodal nanoColloids.
  • Hoskins C, Kong Thoo Lin P, Cheng WP. Fabrication of novel nanosized polymeric micelles for drug delivery.
  • Andre P, Chen S, Hoskins C, Wang L, MacDonald MP. FePt based Hybrid Colloid for nanoThermy Application.
  • Hoskins C. Heat triggered theranostics for pancreatic cancer therapy. Gordon Research Conference. full text>
  • Malekigorji M, Curtis A, Hoskins C, Varbiro G. Hybrid iron oxide-gold nanoparticles as drug delivery vehicles for cancer therapy.
  • Malekigorji M, Curtis ADM, Hoskins C, Varbiro G. Hybrid Iron Oxide-Gold Nanoparticles as Drug Delivery Vehicles for Cancer Therapy.
  • Andre P, Chen S, Hoskins C, Wang L, MacDonald MP, Duce S, Brown S, Lee S, Melzer A, Cuschieri A. Hybrid nanoMaterials for Biocompatible Imaging and Sensor nanoProbes.
  • Alfahad MAM, Hoskins C, Curtis A. LOADING AND RELEASE OF NOVAL GEMCITABINE ADDUCT ONTO HYBRID GOLD IRON-OXIDE NANOPARTILCE FOR PANCREATIC CANCER THERAPY.
  • Alfahad MAM, Hoskins C, Curtis A. LOADING AND RELEASE OF NOVAL GEMCITABINE ADDUCT ONTO HYBRID GOLD IRON-OXIDE NANOPARTILCE FOR PANCREATIC CANCER THERAPY.
  • Chen S, Hoskins C, Wang L, MacDonald MP, Andre P. Magnetic nanoMaterials as Platforms for the Development of Biocompatible hybrid Temperature nanoProbes.
  • Barnett C, Gueorguieva M, Lees M, Darton R, McGarvey D, Hoskins C. Metallic Hybrid Nanoparticles For Image Guided Drug Delivery.
  • Gueorguieva M, McGarvey D, Lees M, Hoskins C. METALLIC HYBRID NANOPARTICLES FOR IMAGE GUIDED DRUG DELIVERY.
  • Malekigorji M, Hoskins C, Varbiro G. Multifunctional iron oxide-gold nanoparticles as drug delivery e=vechiles for liver cancer.
  • Oluwasamni A, Curtis A, Hoskins C. Novel iron oxide-gold nanohybrids with heat triggered surface manipulation.
  • Oluwasanmi A, Curtis A, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat Triggered Surface Manipulation. full text>
  • Oluwasamni A, Curtis ADM, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat Triggered Surface Manipulation.
  • Oluwasanmi A, Curtis ADM, Hoskins C. Novel Iron Oxide-Gold Nanohybrids with Heat-Triggered Surface Manipulation.
  • Barnett C, Cheng WP, Lees M, Curtis A, Kong Thoo Lin P, Hoskins C. Poly(allylamine) magnetomicelles for image guided drug delivery.
  • Barnett C, Cheng WP, Lees M, Curtis ADM, Kong Thoo Lin P, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery.
  • Barnett C, Lees M, Curtis ADM, Kong Thoo Lin P, Cheng WP, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery.
  • Barnett C, Lees M, Curtis A, Kong Thoo Lin P, Cheng WP, Hoskins C. Poly(allylamine) Magnetomicelles for Image Guided Drug Delivery.
  • Roach P and Hoskins C. Remotely triggered scaffolds for controlled degradation in biomedicine.
  • Roach P, McGarvey D, Hoskins C. Remotely triggered scaffolds for controlled release of pharmaceuticals.
  • Roach P, McGarvey D, Lees M, Hoskins C. Stimuli responsive scaffolds for triggered release of pharmaceuticals.
  • Roach P, McGarvey D, Hoskins C. Stimuli Responsive Scaffolds for Triggered Release of Pharmaceuticals.
  • Alfahad M, Hoskins C, Curtis A. Synthesis of novel hybrid nanoparticle-prodrug constructs for pancreatic cancer therapy. full text>
  • Alfahad M, Hoskins C, Curtis A. Synthesis of novel hybrid nanoparticulate-prodrug constructs for pancreatic cancer therapy. full text>
  • Alfahad MAM, Hoskins C, Curtis A. Synthesis of novel hybrid nanoparticulate-prodrug constructs for pancreatic cancer therapy.
  • Alfahad MAM, Hoskins C, Curtis ADM. Synthesis of Novel Hybrid Nanoparticulate-Prodrug Constructs for Pancreatic Cancer Therapy.
  • Alfahad MAM, Hoskins C, Curtis ADM. Synthesis of Novel Hybrid Nanoparticulate-Prodrug Constructs for Pancreatic Cancer Therapy.
  • Hoskins C. Temperature activated theranostics for pancreatic cancer. full text>
  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. Temperature controlled theranostics for pancreatic cancer.
  • Hoskins C. Temperature controlled theranostics for pancreatic cancer.
  • Malekigorji M, Kong Thoo Lin P, Lees M, Gueorguieva M, Curtis A, Hoskins C. TEMPERATURE CONTROLLED THERANOSTICS FOR PANCREATIC CANCER. full text>
  • Al Shakarchi W, Varbiro G, Curtis A, Hoskins C. The co-administration of anticancer and pro-apoptotic agents as novel approach in liver cancer therapy. full text>
  • Hoskins C, Kong Thoo Lin P, Cheng WP. The use of novel amphiphilic polymer to enhance aqueous solubility of hydrophobic drugs.
  • Hoskins C, Kong Thoo Lin P, Cheng WP. The use of novel amphiphilic polymer to enhance aqueous solubility of hydrophobic drugs.
  • Hoskins C, Kong Thoo Lin P, Cheng WP. The use of novel poly(allylamine) based amphiphilic polymers to enhance the aqueous solubility of hydrophobic drugs.
  • Alsuraifi A, Curtis A, Hoskins C. Thermoresponsive copolymer: (HPMA-CO-(APMA-R))-co-PEG polymer synthesis and physiochemical characterization. full text>
  • Alsuraifi A, Curtis A, Hoskins C. Thermoresponsive copolymer: HPMA-co-AMPA-R polymer synthesis and physiochemical characterization. full text>

I welcome applications from students who wish to undertake PhD postgraduate studies in my team. Former, and current, postgraduate students include UK nationals as well as overseas students from the Middle East and India, undertaking full-time studies in my laboratory. Interested students can contact me directly on c.hoskins@keele.ac.uk to discuss potential projects as well as the application process for these degrees.

My current research interests are in Nanopharmaceutics. Nanopharmaceutics is a form of nanotechnology that involves the formulation of medicines into very small dosage forms suitable for administration by various routes as required, intravenously for example (nanomedicine). Often drug molecules have undesirable properties: For example, drugs may not be very soluble in water or they may not be absorbed well by the body which hinders their usage. These drugs require careful formulation in order for them to be administered to patients effectively and display their proposed therapeutic effect. Traditional formulation strategies do not live up to the high demand in recent years where approximately 60% of all new drugs under development are classed as practically insoluble in water, hence the increase in nanomedicine research worldwide. The most common nano-systems for drug formulation are core-shell based systems. Many of these systems have undergone the rigors of regulatory testing and are now licensed for use in the clinic across the globe.

The nano-structures act as chaperones for the drug molecules, carrying their cargo past the body’s defense systems to their intended target site, thus avoiding any premature drug degradation or metabolism. The nano-carriers themselves are relatively simple and cheap to make and they can be easily tailored for application. This tailoring may include inclusion of specific functional groups which help the particle reach their destination more easily or confer additional properties, such as fluorescence in order for their journey after administration to be tracked.

Nanopharmaceutics research has experienced exponential growth internationally in the past ten years. Here in ISTM we have a highly motivated and interdisciplinary Nanopharmaceutics team who strive to drive forward innovation in this area. Our area of research spans across the boundaries of chemistry, physics and the life sciences with an aim to produce novel nanomedicines for a wide variety of different diseases with a special focus on pancreatic cancer. For more information please have a look at my group website:

https://www.keele.ac.uk/pharmacy/research/nanopharmaceutics/

Or contact me directly.